CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Janssen Research & Development, LLC
Genmab
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Janssen Cilag S.A.S.
Eli Lilly and Company
Juno Therapeutics, a Subsidiary of Celgene
Dana-Farber Cancer Institute
The First Affiliated Hospital with Nanjing Medical University
M.D. Anderson Cancer Center
VA Office of Research and Development
Ascentage Pharma Group Inc.
Gruppo Italiano Malattie EMatologiche dell'Adulto
IRCCS San Raffaele
IRCCS San Raffaele
Karolinska University Hospital
Institute of Hematology & Blood Diseases Hospital, China